Minerva Neurosciences, Inc.

NasdaqCM:NERV 株式レポート

時価総額：US$234.3m

Minerva Neurosciences 過去の業績

過去 基準チェック /06

Minerva Neurosciencesの収益は年間平均-45.9%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 109.1%割合で 減少しています。

主要情報

-45.92%

収益成長率

-17.27%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率-109.07%
株主資本利益率n/a
ネット・マージンn/a
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

Seeking Alpha • Oct 17

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences (NASDAQ:NERV), a biotech focused on central nervous system diseases, announced Monday that the FDA issued a "refusal to file" letter regarding its marketing application for roluperidone, a treatment targeted at schizophrenia patients. Without detailing reasons for the refusal, NERV said that the FDA had notified the company could request a Type A meeting to discuss the contents of the letter. Schizophrenia is a mental illness affecting an estimated 20M people globally.  "We are disappointed that the FDA has not accepted our NDA for roluperidone," Chief Executive Remy Luthringer remarked, adding, "the company intends to request a Type A meeting and looks forward to continued discussions with the FDA." NERV shares are currently on hold for trading.
Seeking Alpha • Aug 29

Minerva Neurosciences: Biotech On The Move

Summary NERV stock price has been on fire in recent days. Minerva Neurosciences' troubled roluperidone is just about its lone project candidate. Minerva's financial condition is fraught but adequate for the situation. Minerva Neurosciences (NERV) is a name I have not followed, nor even heard of, until its recent run. Its new price action makes for an interesting story. In this article I review its standing as an investment after its wild upswing. Minerva's shares traded with real urgency during the week of 08/22/2022 For Minerva the week preceding this 08/28/2022 writing was the week that was. After closing on Friday 08/19/2022 at $3.11, it hit a high of $5.19 on Monday 08/22/2022. Before market open on 08/22/2022, Minerva filed its long delayed, as hereafter discussed, NDA for its for roluperidone for the treatment of negative symptoms in patients with schizophrenia. Also on Monday, Steve Cohen and Point72 filed a joint ownership 13G advising of acquisition of 470,000 shares, an 8.8% interest in Minerva. After resting a bit on Tuesday, digesting the news, by Wednesday 08/24/2022, Minerva's jets were firing again full steam, hitting a share price high of $8.58. Its volume Wednesday was exceptional leaping to >82 million shares. Thursday 08/25/2022 was another consolidation day. On Friday 08/26/2022 it hit a peak for the week at $10.89, closing out the week at $10.33 on a volume of >61 million shares. Its price for the week from the previous Friday trough of $3.11 to its following Friday peak of $10.89 reflected an increase of >250%. What has Minerva's longer term share movement looked like? The chart below draws out Minerva's share dynamics over recent years: NERV data by YCharts Minerva's steep 05/2020 downdraft (>-81%) following its negative data release for its phase 3 trial for roluperidone in treatment of negative symptoms in schizophrenia dwarfs its recent upswing. Minerva Neurosciences is a one trick pony with the one trick not yet fully mastered When trying to understand a new biotech name, I usually start by trying to run down its pipeline. For Minerva this endeavor was more difficult than typical. Its 2022 10-K atypically included zero help in this regard. I moved on to check out its website. Again atypically, it includes no entry for its "pipeline" as such. However when I searched for the word "pipeline" it took me to its "programs". There I found the following rather desolate entry which satisfied my need for a pipeline: minervaneurosciences.com As a preclinical program, one of many targeting Parkinson's Disease, I give Minerva's MIN-301 no real consideration. By my assessment MIN-301 is inconsequential in any current evaluation of Minerva. So Minerva is all about roluperidone (MIN-101) in treatment of negative symptoms of schizophrenia. Despite its rough road back with its phase 3 data release in 05/2020, Minerva is motoring ahead with this as fast as it can. Its progress has been halting at best as reflected by the following Seeking Alpha news items: 11/02/2020 Minerva schedules a Type C meeting with the FDA to advance its position of confidence in roluperidone and to discuss and define a forward path; 12/01/2020 Minerva and FDA at odds, with Minerva contending that the totality of the data demonstrates substantial evidence of effectiveness of the 64 mg dose, while FDA considers situation problematic for several reasons including inadequately powered phase 3 to show effectiveness; 05/11/2020 Minerva posts results from its Open-Label Extension [OLE] of its late stage roluperidone trial that it characterized as highly favorable in terms of longer term improvements in patients overall functioning "with few serious adverse events and no evidence of somnolence, extrapyramidal side effects or weight gain"; 09/30/2021 Minerva reported a positive bioequivalence study for roluperidone; 11/03/2021 FDA rebuffs Minerva request for a pre-NDA meeting for roluperidone, instead suggesting that a "Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy". It seems that Minerva finally got the point and went ahead with a Type C meeting. On 04/07/2022 it reported minutes from an 03/02/2022 Type C roluperidone meeting, purposed so that Minerva could obtain: ...the FDA’s agreement on the use of roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia in the subgroup of patients with moderate to severe negative symptoms and stable positive symptoms. On 04/13/2022 it set up a slide deck with its "Roluperidone Update Presentation". This was the material it used to illustrate its 04/03/2022 webcast with its Roluperidone Update; as I write on 08/28/2022 this webcast is still on Minerva's website. The summary slide at the close of this presentation addressed key issues raised by the FDA as follows: seekingalpha.com As I write on 08/28/2022, this is where the situation stands with Minerva's 08/22/2022 filing of its roluperidone NDA. Next stop for roluperidone is FDA decision on whether to approve its filing; we should hear on this within 60 days, likely late October. NERV will need to raise additional funds over its near to mid term Minerva seems to have given up on earnings conference calls, having run its last earnings call for Q3, 2021. This is unfortunate because such calls provide a nice add of color to straight earnings press releases and 10-K/Q's. But for whatever reason, current Minerva investors must make do with what's available. As for Minerva's Q2, 2022 earnings press release, it lists the essentials. Most notably it listed Minerva's bare bones liquidity position as of 06/30/2022 at ~$49.9 million. This compares to its cash, cash equivalents and restricted cash of ~$60.9 million as of 12/31/2021. Minerva's Q2, 2022 Statement of Operation below lists it most recent quarterly and semiannual operating expenses as follows: Minerva Q2, 2022 statement of operations excerpt (sec.gov)
Seeking Alpha • Aug 22

Minerva stock rises on filing for FDA approval of schizophrenia therapy

Minerva Neurosciences (NASDAQ:NERV) filed an application to the U.S. Food and Drug Administration (FDA) seeking approval of roluperidone to treat negative symptoms in patients with schizophrenia. The company's new drug application (NDA) was backed by data from two late-stage studies (MIN-101C03 and MIN-101C07) in patients with moderate to severe negative symptoms and stable positive symptoms of schizophrenia. Minerva is seeking approval for the 64-mg dose of roluperidone. "While positive symptoms of schizophrenia are generally well managed with antipsychotics, negative symptoms are often the main burden of illness and can impact the patients’ quality of life as a result of disabilities caused by impaired vocational and social skills," said Executive Chairman and CEO Remy Luthringer. The company noted that there are currently no treatments approved for negative symptoms of schizophrenia in the U.S. NERV +7.89% to $3.35 premarket Aug. 22
分析記事 • Jun 22

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • Jan 26

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 02

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Mar 03

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. ( NASDAQ:NERV ) shareholders should be happy to see the share price up 15% in the last...
分析記事 • Jan 27

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

A look at the shareholders of Minerva Neurosciences, Inc. ( NASDAQ:NERV ) can tell us which group is most powerful...
分析記事 • Dec 23

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Nov 18

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Minerva Neurosciences, Inc. (NASDAQ:NERV) shareholders should be happy to see the share price up 12% in the last...

収支内訳

Minerva Neurosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:NERV 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 260-415180
31 Dec 250-29390
30 Sep 250-149-6
30 Jun 25011100
31 Mar 2506100
31 Dec 2401100
30 Sep 240-31010
30 Jun 240-34100
31 Mar 240-32100
31 Dec 230-30100
30 Sep 230-28100
30 Jun 230-27100
31 Mar 230-29100
31 Dec 220-32110
30 Sep 220-47110
30 Jun 220-49110
31 Mar 220-51120
31 Dec 210-50130
30 Sep 210-36140
30 Jun 210-35150
31 Mar 2141517-8
31 Dec 20412170
30 Sep 2041-21170
30 Jun 2041-27190
31 Mar 200-6917-4
31 Dec 190-72180
30 Sep 190-55199
30 Jun 190-541817
31 Mar 190-541738
31 Dec 180-501735
30 Sep 180-371532
30 Jun 180-361433
31 Mar 180-331231
31 Dec 170-321130
30 Sep 170-411130
30 Jun 170-381127
31 Mar 170-341023
31 Dec 160-311020
30 Sep 160-30920
30 Jun 160-28818
31 Mar 160-29820
31 Dec 150-27819
30 Sep 150-261015

質の高い収益: NERVは現在利益が出ていません。

利益率の向上: NERVは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NERVは利益が出ておらず、過去 5 年間で損失は年間45.9%の割合で増加しています。

成長の加速: NERVの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: NERVは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。

株主資本利益率

高いROE: NERVの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 18:10
終値2026/05/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Minerva Neurosciences, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Brian SkorneyBaird
Jason ButlerCitizens JMP Securities, LLC
Douglas TsaoH.C. Wainwright & Co.